key: cord-0844240-hx1r3350 authors: Mahil, Satveer K; Bechman, Katie; Raharja, Antony; Domingo-Vila, Clara; Baudry, David; Brown, Matthew A; Cope, Andrew P; Dasandi, Tejus; Graham, Carl; Khan, Hataf; Lechmere, Thomas; Malim, Michael H; Meynell, Freya; Pollock, Emily; Sychowska, Kamila; Barker, Jonathan N; Norton, Sam; Galloway, James B; Doores, Katie J; Tree, Timothy; Smith, Catherine H title: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study date: 2021-11-09 journal: Lancet Rheumatol DOI: 10.1016/s2665-9913(21)00333-7 sha: 3ff8f6b4ecefab1b3ab4b2ba3669f3ef0ae965de doc_id: 844240 cord_uid: hx1r3350 BACKGROUND: COVID-19 vaccines have robust immunogenicity in the general population. However, data for individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains scarce. Our previously published cohort study showed that methotrexate, but not targeted biologics, impaired functional humoral immunity to a single dose of COVID-19 vaccine BNT162b2 (Pfizer-BioNTech), whereas cellular responses were similar. Here, we aimed to assess immune responses following the second dose. METHODS: In this longitudinal cohort study, we recruited individuals with psoriasis who were receiving methotrexate or targeted biological monotherapy (ie, tumour necrosis factor [TNF] inhibitors, interleukin [IL]-17 inhibitors, or IL-23 inhibitors) from a specialist psoriasis centre serving London and South-East England. The healthy control cohort were volunteers without psoriasis, not receiving immunosuppression. Immunogenicity was evaluated immediately before, on day 28 after the first BNT162b2 vaccination and on day 14 after the second dose (administered according to an extended interval regimen). Here, we report immune responses following the second dose. The primary outcomes were humoral immunity to the SARS-CoV-2 spike glycoprotein, defined as titres of total spike-specific IgG and of neutralising antibody to wild-type, alpha (B.1.1.7), and delta (B.1.617.2) SARS-CoV-2 variants, and cellular immunity defined as spike-specific T-cell responses (including numbers of cells producing interferon-γ, IL-2, IL-21). FINDINGS: Between Jan 14 and April 4, 2021, 121 individuals were recruited, and data were available for 82 participants after the second vaccination. The study population included patients with psoriasis receiving methotrexate (n=14), TNF inhibitors (n=19), IL-17 inhibitors (n=14), IL-23 inhibitors (n=20), and 15 healthy controls, who had received both vaccine doses. The median age of the study population was 44 years (IQR 33–52), with 43 (52%) males and 71 (87%) participants of White ethnicity. All participants had detectable spike-specific antibodies following the second dose, and all groups (methotrexate, targeted biologics, and healthy controls) demonstrated similar neutralising antibody titres against wild-type, alpha, and delta variants. By contrast, a lower proportion of participants on methotrexate (eight [62%] of 13, 95% CI 32–86) and targeted biologics (37 [74%] of 50, 60–85; p=0·38) had detectable T-cell responses following the second vaccine dose, compared with controls (14 [100%] of 14, 77–100; p=0·022). There was no difference in the magnitude of T-cell responses between patients receiving methotrexate (median cytokine-secreting cells per 10(6) cells 160 [IQR 10–625]), targeted biologics (169 [25–503], p=0·56), and controls (185 [133–328], p=0·41). INTERPRETATION: Functional humoral immunity (ie, neutralising antibody responses) at 14 days following a second dose of BNT162b2 was not impaired by methotrexate or targeted biologics. A proportion of patients on immunosuppression did not have detectable T-cell responses following the second dose. The longevity of vaccine-elicited antibody responses is unknown in this population. FUNDING: NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London; The Psoriasis Association. Individuals with immune-mediated inflammatory diseases were shown to be at increased risk of COVID-19related death compared with the general population. 1 Based on previous research in other infections and registry data collected during the COVI-19 pandemic, 2-4 there has been concern over the detrimental effect of systemic immunosuppressants (the mainstay of treatment of moderate to severe immune-mediated inflammatory diseases) on COVID-19 outcomes. Vaccination is therefore a vital risk mitigating strategy in this population. General population-based studies indicate that two doses of a COVID-19 vaccine provides protection against SARS-CoV-2 infections and related adverse outcomes. 5, 6 However, immunogenicity and clinical effectiveness in patients with immune-mediated inflam matory diseases who are receiving immuno suppressants remains uncertain. These patients were excluded from COVID-19 vaccine trials and most previous studies have focused on seroconversion alone, 7-10 which might not adequately reflect vaccine immunogenicity or correlate with effectiveness. Several countries, including the UK, adopted an extended interval vaccination regimen (up to 12 weeks between doses) to maximise population coverage with a single (prime) vaccine. Compared with the standard 3 week interval, the extended interval regimen has been shown to increase peak antibody responses and improve vaccine efficacy in the general population. 11, 12 The interim findings at day 28 (after one dose) of our longitudinal cohort study of patients with psoriasis showed that methotrexate, but not targeted biological monotherapy, impaired functional humoral immunity in response to a single dose of BNT162b2 (Pfizer-BioNTech), whereas cellular responses were similar, between patients with psoriasis and healthy controls. 13 Emerging larger-scale research in heterogeneous cohorts of patients with immune-mediated inflammatory diseases indicated lower serological and similar cellular responses to two vaccine doses, compared with healthy controls. 14 However, there is a paucity of data on medication-specific effects on the immunogenicity of a second vaccine dose, 15 including against novel, highly transmissible, SARS-CoV-2 variants of concern. We sought to assess the effect of methotrexate and targeted biological monotherapy on early humoral and cellular immune responses after the second dose of BNT162b2 in patients with psoriasis who were vaccinated at an extended dosing interval. We also aimed to gain insight into immunity against the predominant delta variant (B.1.617.2), which has emerged since our interim analysis and presents a challenge to vaccination strategies. 16, 17 We conducted a prospective, longitudinal cohort study in individuals with a dermatologist-confirmed diagnosis of Evidence before this study Two COVID-19 vaccine doses, administered according to an extended interval regimen, are highly efficacious at protecting against SARS-CoV-2 infections and adverse COVID-19 outcomes in the general population. However, data for individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remain scarce. Understanding vaccine immunogenicity in this vulnerable population is of major importance to public and individual health. The interim analysis of our cohort study at day 28 (after one dose) showed that methotrexate but not targeted biologics impaired functional humoral immunity (ie, neutralising antibody responses) to the first dose of the COVID-19 vaccine BNT162b2 (Pfizer-BioNTech), whereas T-cell responses were similar. The OCTAVE study, involving a heterogeneous cohort of patients with immunemediated inflammatory diseases, indicated lower serological and similar T-cell responses to two vaccine doses, compared with healthy controls. No medication-specific effects or functional humoral responses were investigated in the OCTAVE study. No studies have concurrently assessed immunosuppressantspecific effects on serological, neutralising antibody (including against the delta variant) and cellular responses to a second vaccine dose, administered at an extended interval, in patients with immune-mediated inflammatory diseases. We evaluated the effect of methotrexate and biologics targeting tumour necrosis factor, interleukin (IL)-17, and IL-23 on humoral (serological and functional) and cellular immune responses to the second dose of the COVID-19 vaccine BNT162b2 in individuals with psoriasis. All patients receiving immunosuppressants and all healthy controls seroconverted (ie, had detectable spike-specific IgG) at 14 days following the second dose. Neutralising antibody titres against wild-type SARS-CoV-2, alpha (B.1.1.7), and delta (B.1.617.2) variants were similar in patients receiving methotrexate, targeted biologics, and healthy controls. Whereas a proportion of healthy controls and patients had undetectable spike-specific T-cell responses (interferon-γ, IL-2, or IL-21) after the first dose, all controls had detectable T-cell responses at 14 days after the second dose. By contrast, a proportion of patients receiving immunosuppressants had undetectable spike-specific T-cell responses following the second dose (similar to after the first dose). The magnitude of response was similar in patients receiving methotrexate, targeted biologics, and controls. These findings indicate that functional humoral immunity at 14 days after a second dose of the BNT162b2 COVID-19 vaccine was not impaired by methotrexate or targeted biologics. A proportion of patients on immunosuppression did not have detectable T-cell responses after the second dose. The durability of antibody responses in the context of undetectable cellular responses is uncertain, underscoring the importance of ongoing risk mitigation efforts and research into further vaccine doses in this population. psoriasis who were receiving methotrexate or targeted biological monotherapy (tumour necrosis factor [TNF] inhibitors, interleukin [IL]-17 inhibitors, or IL-23 inhibitors). The healthy control cohort were volunteers without psoriasis and not receiving systemic immunosuppression. We recruited all individuals from a specialist psoriasis centre (Severe Psoriasis Service, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK) serving London and South-East England. We excluded individuals from the main analysis if they had previous SARS-CoV-2 infection (serologically confirmed) or had received the ChAdOx1 nCoV-19 vaccine, as described previously. 13 This study was approved by the London Bridge Research Ethics Committee (REC reference 06/Q0704/18). All participants provided written informed consent before enrolment. Clinical and safety data and blood samples were collected at three study visits: baseline (same day of and immediately before vaccination), 28 days after the first dose of BNT162b2 (±2 days), and 14 days (±2 days) after the second dose. The second dose was administered according to the UK Government extended interval vaccine policy of up to 12 weeks. Immune responses following the first dose were previously described. 13 Here, we report findings following the second vaccine dose. Plasma and peripheral blood mononuclear cells were isolated from blood samples and processed as previously described. 13 Humoral immunity was based on seroconversion, assessed using ELISAs for IgG specific for the SARS-CoV-2 spike glycoprotein and the functional capacity of participants' plasma to neutralise the HIV-1 viral particles pseudotyped with spike of prototypic (wild-type) strain of SARS-CoV-2, alpha (B.1.1.7) variant, or delta (B.1.617.2) variant. 18 Seroconversion was defined as IgG four-fold above the background at the first dilution point (1:25) . A threshold half maximal effective concentration (EC 50 ) was used for anti-SARS-CoV-2 IgG titres, at which serological responses were classified as positive. Neutralisation activity is presented as 50% inhibitory dilution (ID 50 ). Vaccine-induced cellular immunity was deter mined via spike-specific T-cell production of interferon-γ and IL-2 (type 1 helper T cell [Th1] cytokines), and IL-21 (T follicular helper cell [Tfh] cytokine). These responses were quantified following stimulation with two peptide pools spanning the entire length of the SARS-CoV-2 spike glycoprotein. Direct FluoroSpot assays were used to detect interferon-γ and IL-2, and direct ELISpot assays were used to detect IL-21. Receiver operator characteristic curve analysis was used to establish threshold values to determine a positive response for the total T-cell response (combined interferon-γ, IL-2, and IL-21) and for each individual cytokine. A threshold value of 30 cytokine-secreting cells per million peripheral blood mononuclear cells was established, at which level the total T-cell response was classified as positive. The primary outcomes were humoral immunity to the SARS-CoV-2 spike glycoprotein 14 days after the second dose of BNT162b2, defined as neutralising antibody responses to wild-type, alpha (B.1.1.7), and delta (B.1.617.2) SARS-CoV-2 variants, and spike-specific T-cell responses (ie, production of interferon-γ, IL-2, IL-21, or a combination thereof). The key exposure measure was immunosuppressive treatment type. We tested two predetermined hypotheses: first, that after the second dose of BNT162b2, patients taking methotrexate would have lower humoral immunity, cellular immunity, or both compared with healthy controls; and second, that patients taking methotrexate would have lower humoral immunity, cellular immunity, or both compared with patients taking targeted biological therapy (TNF inhibitors, IL-17 inhibitors, or IL-23 inhibitors). Adverse events were classified as local or systemic, and graded as mild (no or minimal interference with participants' activity and no or minimal medical intervention required), moderate (limitation in activity and medical intervention required), severe (marked limitation in activity and medical intervention required). Demographic and clinical characteristics and humoral and cellular immunogenicity were summarised using descriptive statistics. Statistical imbalance across the treatment groups was calculated with the Kruskal-Wallis or χ² test. Further comparisons were made using a linear regression model with robust estimates of variance to derive 95% CIs and p values. The regression models incorporated log transformed immunogenicity meas ures as the dependent variable, and methotrexate versus healthy controls or methotrexate versus biologics as a binary independent variable. We adjusted for age and sex. Model diagnostics were evaluated to check for heteroskedasticity and linearity assumptions. A 5% α level was used for significance testing. The study was exploratory in nature, and therefore no correction for multiple hypothesis testing was made. Data were analysed in Stata (version 16). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Proximity of methotrexate or biologic to vaccine dose 1, days Proximity of methotrexate or biologic to vaccine dose 2, days Time between vaccine doses, weeks All values are given as n (%) or median (IQR), unless otherwise specified. Statistical imbalance of the baseline characteristics across the treatment groups presented by either Kruskal-Wallis or χ2. BMI=body-mass index. TNF=tumour necrosis factor. IL=interleukin. Between Jan 14 and April 4, 2021, 121 individuals were enrolled, of whom 39 (32%) were excluded from the final analysis on the basis of immunisation with the ChAdOx1 nCoV-19 vaccine (n=10), previous history of COVID-19 (n=10), switching immunosuppression therapy between the first and second dose (n=2; one individual switched from methotrexate monotherapy to adalimumab monotherapy, and the second individual switched from certolizumab monotherapy to cotherapy with certolizumab and methotrexate), or loss to follow up after the first vaccine dose (n=17; figure 1 ). The final analysis (n=82) included 67 individuals with psoriasis receiving therapeutic immunosuppression, including methotrexate (n=14), TNF inhibitors (n=19), IL-17 inhibitors (n=14), IL-23 inhibitors (n=20), and 15 healthy volunteers (the control group). The median age of the total study population was 44 years (IQR 33-52), with 43 (52%) males and 71 (87%) participants of White ethnicity (table 1, appendix p 1). Among the 67 patients, the median duration of psoriasis was 21 years (IQR 15-33); all had well controlled psoriasis, as indicated by their baseline disease severity. No participants receiving immunosuppression monotherapy reported a pause or stop in medication before or following BNT162b2 vaccination. Of those who were receiving methotrexate, the median dose of methotrexate was 15·0 mg (range 5·0-22·5 mg per week. No patients were receiving concomitant corticosteroid therapy. The time between the last dose of immunosuppression and vaccination was similar for vaccine doses 1 and 2 in all therapy groups (table 1). The median spacing between vaccine doses was 10·0 weeks (IQR 9·3-10·9); the control cohort had a slightly longer spacing between doses (11·0 weeks [10·3-11·4]) compared with those on immunosuppression (9·9 weeks [9·1-10·6]; p<0·0001). No participants reported COVID-19 during the study. Mild adverse events after the second vaccine dose were reported by 42 (63%) of 67 patients receiving immunosuppression compared with 12 (80%) of 15 controls (appendix p 2, 5, 6). Adverse events of moderate severity were reported five times in patients with psoriasis after the second dose: headache (n=1), malaise (n=2), and fatigue (n=2). The commonest local adverse effect was pain at the injection site and the commonest systemic adverse event was fatigue (appendix pp 2, 5, 6). Worsening psoriasis was reported by eight (12%) of 67 (95% CI 5-22) patients after the second vaccination. Data for humoral immunogenicity in response to the second dose were missing for three patients with psoriasis; one each receiving a TNF inhibitor, IL-17 inhibitor, and IL-23 inhibitor. Cellular data were missing for one healthy control and four patients; two on IL-23 inhibitors, one on methotrexate, and one on an IL-17 inhibitor. All 79 participants with humoral immunogenicity data (100% [95% CI 96-100]) seroconverted after the second BNT162b2 dose (table 2, figure 2 ). The second dose successfully boosted spike-specific IgG titres in all groups. The fold change in spike-specific IgG titre between doses 1 and 2 was highest in patients receiving methotrexate (median fold change 42 [IQR 23-159]) compared with healthy controls (20 ) and patients on targeted biologics (33 All study participants had detectable neutralising antibodies against wild-type SARS-CoV-2 following the second vaccine dose, and all groups showed increased neutralising antibody titres against wild-type SARS-CoV-2 and the alpha variant after the second dose compared to the first ( figure 3A, B) . The fold change in neutralising antibody titres against wild-type SARS-CoV-2 between the first and second dose was significantly higher in patients receiving methotrexate ( figure 3C ). There was no association between neutralising antibody titres and the time interval between the first and second dose of vaccine (appendix p 7). There was no evidence of induction or boosting of total T cell responses (as evidenced by production of interferon-γ, IL-2, or IL-21) between the first and second vaccine doses in patients receiving methotrexate (median fold change of log cytokine production was 1·0 [IQR 0·4-1·3; appendix p 8 figure 4) . In regression analyses, methotrexate was not associated with lower cellular immunogenicity compared with healthy controls (β=-0·30 [95% CI -1·07 to 0·46], p=0·42) or compared with targeted biological therapy (β=0·07 [-0·57 to 0·70], p=0·84). There was no association between T cell response and the time interval from the first and second dose of vaccine (appendix p 10) or clear difference in clinical or demographic characteristics between indi viduals who did and did not mount a T cell response (appendix p 4) In this longitudinal cohort of individuals with psoriasis, monotherapy with methotrexate or targeted biological drugs did not significantly impair serological or functional humoral responses at 14 days following the second dose of BNT162b2, including against the delta variant. The second vaccine dose resulted in sero conversion in all participants. Whereas all controls had detectable total T-cell responses following the second vaccine dose, 18 (29%) of 63 individuals taking therapeutic immunosuppression had no evidence of T-cell responses. Our findings indicate that a second dose of BNT162b2 vaccine, delivered according to an extended interval regimen, is successful in inducing antibody responses in individuals receiving methotrexate and targeted biologics. However, compared with healthy controls, a lower proportion of patients taking immunosuppressants had detectable T-cell responses or evidence of a boost in T-cell immunity following the second dose. Our interim analysis findings showed that a proportion of both the control and immunosuppressed cohort had undetectable T-cell responses to the first vaccine dose. 13 Following a second dose, all individuals in the control group demonstrated T-cell responses, whereas a proportion of immunosuppressed patients still had undetectable responses. Our results, albeit in a cohort of limited size, suggest that cellular immunity might diminish over time in some immunosuppressed individuals despite a second vaccine dose. An absence of boosting in cellular immunity in the context of immunosuppression supports findings from the OCTAVE study, in which patients with inflammatory arthritis and inflammatory bowel disease (receiving varying immunosuppressant therapies) had similar interferon-γ responses after both the first and second vaccine doses. 14 In another recent study of a heterogenous group of patients with immune-mediated inflammatory diseases, patients receiving methotrexate did not have an increase in CD8 + T-cell activation after two vaccine doses. 19 The importance of generation and boosting of T-cell responses for vaccine effectiveness is incompletely understood. T-cell immunity can influence long-term humoral immune dynamics; emerging research indicates that robust induction of antigen-specific T cells by mRNA vaccines enables durable neutralising antibody responses. 20 The generation of long-term antibody-mediated immunity depends on the germinal centre reaction, 21 which requires cooperation between antigen-specific T cells and B cells. Tfh cells sustain germinal centre responses, and their importance in coordinating humoral immunity after vaccination was underscored in research showing that detection of Tfh responses before a second vaccine dose correlated with neutralising antibodies after the second dose. 20 Spikespecific antibodies following two vaccine doses have been shown to wane over time in immunocompetent individuals, 22 but the kinetics of antibody responses in immunosuppressed patients is unknown. Our data indicate that a higher proportion of patients receiving immunosuppression do not have detectable Tfh cell responses following the second vaccine dose compared with controls (despite demonstrating antibody responses at 14 days after second dose; appendix pp 3, 9) . Hence, assessing the longevity of vaccine-elicited antibody responses in these immuno suppressed patients and their ability to generate robust antibody responses on antigen re-exposure is important and might help to inform public health policy on the timing of subsequent vaccine doses and ongoing need for risk mitigating measures to reduce exposure to SARS-CoV-2. Our humoral data at 14 days after a second vaccination indicate 100% seroconversion in patients receiving immuno suppression and similar functional humoral responses to healthy controls. Although our interim findings suggested lower serological responses to the first vaccine dose in patients taking immunosuppression compared with controls, with impaired functional humoral responses in those on methotrexate, 13 the current data indicate successful boosting of antibody responses in all patients. Our data align with emerging findings from the CLARITY-IBD study, 15 showing that a second vaccine dose led to seroconversion in most patients treated with the TNF inhibitor infliximab. Although neutralising responses or drug-specific effects were not assessed in OCTAVE, robust sero con version (98%) was also detected following the second vaccine dose in patients with inflammatory arthritis. 14 In that study, 14 lower median antispike IgG titres were identified in patients with immunemediated inflammatory diseases compared with controls. It is currently unclear whether this could translate to lower levels of protection. 23 Although not statistically sig nificant, the data from our limited sample size also suggest numerically lower levels of anti-spike IgG in immunosuppressed patients, compared with controls. Similar trends were identified in other cohorts of patients with immune-mediated inflammatory diseases, 9, 19, 24 and these findings have raised questions about whether dose modification of methotrexate or temporary discontinuation could enhance immune responses to COVID-19 vaccines. As this strategy was shown to be successful in promoting immunogenicity to the influenza vaccine, 25 a 2 week interruption in methotrexate after the COVID-19 booster is currently under investigation in a multicentre, randomised controlled trial. 26 Assessments of functional humoral immunity in this study (which were reassuringly similar among all groups in our dataset), T-cell immunity, and clinical effectiveness will be important. As the pandemic progresses, assessing immune crossreactivity with novel variants of concern following vaccination is vital. There is a relative paucity of data for vaccine immunogenicity against the highly trans missible delta variant, 27, 28 which is now the dominant variant worldwide. Population-level data indicate that the risk of COVID-19-related hospital admission associated with the delta variant is approximately double that of the alpha variant, with risk particularly increased in those with multimorbidities. 16 Our data suggesting that methotrexate or targeted biologics do not impair neutralising antibody capacity against the delta variant are reassuring; however, there remains an urgent need to correlate immune findings with clinical effectiveness data. Our study cohort is relatively homogeneous, and each study group (methotrexate, targeted biologics, healthy controls) was well matched with respect to clinical and demographic characteristics. No participants had a previous history of COVID-19 infection, and all had baseline or prevaccination data available. As a result of previously described age-related heterogeneity in responses to COVID-19 vaccines, 29, 30 we enrolled a relatively young cohort (average age 44 years). All patients had well controlled psoriasis, enabling an investigation of drugspecific, rather than disease-specific, effects of vaccination. The immuno genicity assays used are highly reproducible. However, the number of participants and duration of follow-up are limited, hence these data should be interpreted with caution. It is possible that differences would become statistically significant with a larger sample size. It is also unknown how thresholds of antibody and cellular responses, which are based on levels in unvaccinated individuals and hence set at a conservative level, relate to clinical outcome. Patients with psoriasis who were not receiving immunosuppressants were not included, and most participants were of White ethnicity. All participants received BNT162b2 and no other vaccine types were included. It is also important to acknowledge that we have not corrected for multiple hypothesis testing as this study was exploratory. Larger and longer-term multicentre studies with more diverse study populations are required to validate and extend our findings, particularly in relation to the impact of an extended interval vaccination on the evolution of vaccine immune responses in immuno suppressed cohorts over time. Although our healthy control cohort received their second vaccine dose on average 1 week earlier than the immunosuppressed patients, our analysis indicates that this difference in timing is unlikely to affect immunogenicity. Studies involving cohorts of patients with different immunemediated inflammatory diseases are required to understand the generalisability of our treatment-specific findings across diseases. Our findings contribute to an important evidence base for informing future public health policy on prioritising populations for additional vaccine doses. Pending clinical effectiveness data, the current study supports the prioritisation of patients with immune-mediated inflammatory diseases receiving therapeutic immunosuppression to receive a further vaccine dose, since a proportion of our immunosuppressed cohort had undetectable cellular responses following a second dose (in contrast to healthy controls). Although we detected robust serological and neutralising antibody responses (including against the delta variant) in individuals receiving methotrexate and targeted biological monotherapy 14 days after the second vaccine dose, the immune correlates of vaccine effectiveness remain to be determined. The association between virus neutralisation and protection warrants investigation, as does the identification of clinically relevant seroprotection titres and the contribution of T-cell responses to protection. Long-term durability of antibody responses in the context of absent cellular responses is uncertain and merits further study. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform Effect of IBD medications on COVID-19 outcomes: results from an international registry Factors associated with adverse COVID-19 outcomes in patients with psoriasis -insights from a global registrybased study Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK's COVID-19 Infection Survey Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort Absence of humoral response after two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases: a case series Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies Extended interval BNT162b2 vaccination enhances peak antibody generation in older people Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity -the OCTAVE trial Infliximab is associated with attenuated immunogenicity to BNT162b2 and SARS-CoV-2 vaccines in patients with IBD SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immunemediated inflammatory disease Rapid induction of antigenspecific CD4 + T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study Covid-19 breakthrough infections in vaccinated health care workers Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial Multi-centre randomised controlled trial examining the effects of interrupting low-dose methotrexate treatment for two weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions, and nested mechanistic study SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom We are happy to share data on request to the corresponding author.